Spotlight On... New study IDs a fresh approach on fighting AML; New screening method for antibiotics; Biologic markers found for mental disorders; 'Failed' drug shows promise for bipolar disorder; and more...

Two molecules--Hif-1alpha and Hif-2alpha--work together to stop the formation of leukemic stem cells in acute myeloid leukemia, according to a new study from the University of Edinburgh. "Our discovery that Hif-1alpha and Hif-2alpha molecules act together to stop leukemia development is a major milestone in our efforts to combat leukemia," said Professor Kamil R Kranc, Cancer Research UK Senior Fellow at the MRC Centre for Regenerative Medicine. "We now intend to harness this knowledge to develop curative therapies that eliminate leukemic stem cells, which are the underlying cause of AML." Release

> Biologists at UC San Diego say they have developed a new method to identify and "characterize new antibiotics can be employed to screen natural products quickly for compounds capable of controlling antibiotic resistant bacteria." Release

> Researchers at the University of Georgia say they have found biological markers that make it possible to classify mental disorders with greater precision. Release

> Reviewing a list of "failed" drugs, Oxford scientists say that the stroke drug ebselen demonstrated promise as a replacement therapy for bipolar disorder. Release

Suggested Articles

A newfound link between BMAL1, a protein involved in circadian rhythms, and triple-negative breast cancer could point to new treatment strategies.

Combining a DYRK1A inhibitor with popular GLP-1 receptor agonists regenerates insulin-producing beta cells, Mount Sinai scientists found.

Arming a peptide taken from the virus that causes foot-and-mouth disease in cows with the payload tesirine shows promise against pancreatic cancer.